These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9039594)

  • 1. Contrast agents for MR imaging of the liver.
    Low RN
    J Magn Reson Imaging; 1997; 7(1):56-67. PubMed ID: 9039594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].
    Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W
    Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations.
    Martin DR; Semelka RC; Chung JJ; Balci NC; Wilber K
    Magn Reson Imaging; 2000 Oct; 18(8):955-63. PubMed ID: 11121698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.
    Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC
    Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble-type hepatobiliary contrast agents for MR imaging.
    de Haën C; Gozzini L
    J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
    [No Abstract]   [Full Text] [Related]  

  • 8. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
    Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
    Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contrast medium enhanced magnetic resonance tomography of liver metastases: positive versus negative contrast media].
    Hammerstingl RM; Schwarz W; Hochmuth K; Staib-Sebler E; Lorenz M; Vogl TJ
    Radiologe; 2001 Jan; 41(1):24-39. PubMed ID: 11220095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced magnetic resonance imaging of the liver with Mn-DPDP for known or suspected focal hepatic disease.
    Bernardino ME; Young SW; Lee JK; Weinreb J
    Invest Radiol; 1991 Nov; 26 Suppl 1():S148-9; discussion S150-5. PubMed ID: 1808113
    [No Abstract]   [Full Text] [Related]  

  • 19. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory pseudotumor of the liver: MRI with mangafodipir trisodium.
    Materne R; Van Beers BE; Gigot JF; Horsmans Y; Lacrosse M; Pringot J
    J Comput Assist Tomogr; 1998; 22(1):82-4. PubMed ID: 9448766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.